NanoCor Therapeutics Inc.

With rights to a novel gene that it believes will help protect and repair damaged heart tissue and an adeno-associated virus (AAV) gene therapy delivery system, NanoCor Therapeutics is currently developing preclinical data to support the use of its gene therapy to treat chronic heart failure patients awaiting a heart transplant.

870 Martin Luther King Jr. Blvd.

Chapel Hill, NC 27514

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cell Therapies

More from Advanced Therapies